Novo’s CEO Is Ready to Go ‘Very Big’ in Hunt for Obesity Deals
Financial Post
byBloomberg News
Tuesday, January 13, 2026 at 10:07 PM
Novo Nordisk A/S is back on the hunt for deals to boost its obesity portfolio after losing US biotech Metsera Inc. in a bidding war with Pfizer Inc. late last year.
Mike Doustdar, chief executive officer of Novo Nordisk A/S, during a Bloomberg Television interview at the JPMorgan Healthcare Conference in San Francisco, California, US, on Tuesday, Jan. 13, 2026. … [+4945 chars]
Language
eng
Source
Financial Post
Category
general
Added
1d ago
